COMMODORE CAPITAL LP
Q3 2026 Form 13-F

NEW YORK, NEW YORK
CIK 0001831942 · CRD 304370 · SEC-registered investment adviser
$1.3B Reported Value Total

COMMODORE CAPITAL reports 3 total accounts under management (AUM). There are 3 discretionary accounts valued at $2,369,313,969, and 0 non-discretionary accounts.

Source: Form ADV filed * Note that certain holdings are exempt from Form 13-F reporting, so the AUM totals may be greater than the Form 13-F total.
SEC Registered Discretionary Manager
Private funds (Form ADV)
1 fund · $2.4B gross asset value
Hedge Fund: $2.4B
Source: Form ADV filed 2026-03-31
Reported value
$1.3B
Quarter over quarter
-6.4%
Holdings
37
Top-10 concentration
65.2%

Key People

Form ADV owners & control persons
Robert Egen Turrell Atkinson
MEMBER
Michael Jonathan Kramarz
LIMITED PARTNER
Ameya Vikas Bapat
CHIEF COMPLIANCE OFFICER, CHIEF OPERATING OFFICER, GENERAL COUNSEL

Filing Navigation

13F Metrics

Loading 13F Metrics

Q3 2026 13F record

Q3 2026 13F filing summary

Q3 2026 Form 13F portfolio summary
Period of report September 30, 2026
Filed November 16, 2026
Form 13F-HR
Reported value $1.3B
Positions 37
Change in reported value -23.1%
New positions 11
Exited positions 7
Position turnover 40.9%
Top-10 concentration 65.2%

13F filings by quarter

Form 13F filings by quarter
Quarter Positions Value
Q3 2026 13F
Filed Nov 16, 2026
37 $1.3B
Q2 2026 13F
Filed Aug 14, 2026
33 $1.7B
Q1 2026 13F
Filed May 15, 2026
36 $1.7B
Q4 2025 13F
Filed Feb 17, 2026
33 $1.5B
Q3 2025 13F
Filed Nov 14, 2025
37 $2.0B
Q2 2025 13F
Filed Aug 14, 2025
33 $1.4B
Q1 2025 13F
Filed May 15, 2025
31 $1.4B
Q4 2024 13F
Filed Feb 14, 2025
31 $1.4B
Q3 2024 13F
Filed Nov 14, 2024
36 $1.6B
Q2 2024 13F
Filed Aug 14, 2024
35 $1.5B
Q1 2024 13F
Filed May 15, 2024
39 $1.5B
Q4 2023 13F
Filed Feb 14, 2024
32 $1.1B
Q3 2023 13F
Filed Nov 14, 2023
30 $855.5M
Q2 2023 13F
Filed Aug 14, 2023
26 $889.8M
Q1 2023 13F
Filed May 15, 2023
32 $656.8M
Q4 2022 13F
Filed Feb 14, 2023
35 $663.5M
Q3 2022 13F
Filed Nov 14, 2022
30 $621.9M
Q2 2022 13F
Filed Aug 15, 2022
24 $473.0M
Q1 2022 13F
Filed May 16, 2022
27 $447.7M
Q4 2021 13F
Filed Feb 14, 2022
25 $431.8M

4 earlier quarters on file — choose one from the quarter menu above.

Top 20 holdings · Q3 2026

Largest Q3 2026 13F positions by reported value
# Holding Reported value % of portfolio
1 RLAY RELAY THERAPEUTICS INC $216.6M 16.78%
2 ELVN ENLIVEN THERAPEUTICS INC $150.1M 11.63%
3 ALKS ALKERMES PLC $116.5M 9.03%
4 ANRO ALTO NEUROSCIENCE INC $69.5M 5.39%
5 SYRE SPYRE THERAPEUTICS INC $62.3M 4.83%
6 AMLX AMYLYX PHARMACEUTICALS INC $58.2M 4.51%
7 LBRX LB PHARMACEUTICALS INC $49.2M 3.81%
8 DMRA DAMORA THERAPEUTICS INC $41.3M 3.2%
9 COGT COGENT BIOSCIENCES INC $40.5M 3.14%
10 TYRA TYRA BIOSCIENCES INC $37.7M 2.92%
11 CLDX CELLDEX THERAPEUTICS INC NEW $32.4M 2.51%
12 PHVS PHARVARIS N V $29.3M 2.27%
13 SRZN SURROZEN INC $28.5M 2.21%
14 KRSA KORSANA BIOSCIENCES INC $28.1M 2.17%
15 SGMT SAGIMET BIOSCIENCES INC $27.2M 2.11%
16 DFTX DEFINIUM THERAPEUTICS INC $26.6M 2.06%
17 ADRX ADARX PHARMACEUTICALS INC $25.1M 1.95%
18 EDIT EDITAS MEDICINE INC $22.8M 1.77%
19 ENTX ENTERA BIO LTD $21.4M 1.66%
20 ATTO ATTOVIA THERAPEUTICS INC $19.9M 1.54%

Values as reported on the Q3 2026 Form 13F. Every position is in the holdings table below.

Filing Details

Loading Activities
Loading Sector Allocation
Crunching numbers

Performance

Loading Performance

Similar Managers

Finding Similar Managers

Potential New Buys

Finding Potential New Buys

Holdings

Building table
Loading SEC filing data
Loading Form 4 Filings

Beneficial Ownership (Schedule 13D/13G)

Loading 13D/G filings